

ASX ANNOUNCEMENT

CHANGE OF COMPANY SECRETARY

Sydney, 6 October 2010: Cellmid Limited (ASX: CDY) advises that Company Secretary and Financial Controller Andrew Bursill has resigned from his position and Nicholas Falzon has been appointed as Cellmid's new Company Secretary and Financial Controller, effective immediately.

Mr Bursill has served Cellmid as Company Secretary and Financial Controller since 10 December 2008. He has been instrumental in achieving several key milestones in the Company's development, including the restructuring of a convertible note debt, which allowed the recapitalisation of Cellmid in early 2009.

"We thank Andrew for his outstanding contribution to Cellmid's development" said Dr David King, Chairman of the Company. "Andrew's experience and professionalism has been essential in driving the company's progress" added Maria Halasz, CEO of Cellmid.

Nicholas Falzon, Cellmid's newly appointed Company Secretary and Financial Controller, is a member of the Institute of Chartered Accountants, an Associate of the Taxation Institute of Australia and a Registered Tax Agent. He is a Director at accounting and consultancy firm Lawler Partners, where he is responsible for a client portfolio including listed and unlisted businesses.

Nicholas has been involved with Cellmid since 2006 as accountant and tax consultant. In particular, he has been responsible for Cellmid's R&D tax concession submissions, including applications for tax offset. "We look forward to continue to benefit from Nicholas' extensive accounting and taxation experience, in addition to his contribution as Company Secretary" said CEO Maria Halasz.

End

Contact:

Maria Halasz, CEO

M +61 416 008 413

About Cellmid Limited (ASX: CDY)

Cellmid Limited is a biotechnology company listed on the Australian Stock Exchange. The Company is the owner of the most comprehensive intellectual property portfolio around midkine globally. Midkine is a significant novel therapeutic and diagnostic target. It is a native protein expressed during early cancer formation as well as at the onset of a number of inflammatory processes. Cellmid is committed to the commercialisation of its portfolio of therapeutic and diagnostic products

Investment in biotechnology companies

There are a number of inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Cellmid recommends that investors seek professional advice before making an investment in its shares.